Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957242 · ClinicalTrials.gov registry record · Phase 3
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
NCT00957242: Clinical Trial Phase 3 study, sponsored by Duke University.
NCT00957242 is a Phase 3 study that was terminated before completion, run by Duke University. The registered enrollment target is 145 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00957242, a Phase 3 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
Study Summary
This study will test the effectiveness of warfarin in patients with IPF. Approximately 256 patients will be randomized 1:1 to either warfarin or placebo. Patients will return at week 1 for a safety review and every 16 weeks for 48 weeks. The primary endpoint in the study is the time to either death, non-bleeding/non-elective hospitalization, or a drop of greater than 10% in forced vital capacity (FVC) from baseline.
Primary Outcome
Death, non-bleeding/non-elective hospitalization, or \>10% drop in forced vital capacity.
Interventions
- DRUG placebo
- DRUG warfarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Why NCT00957242 stopped before completion
NCT00957242 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00957242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00957242 about?
NCT00957242 is a clinical study titled "AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis". This study will test the effectiveness of warfarin in patients with IPF. Approximately 256 patients will be randomized 1:1 to either warfarin or placebo. Patients will return at week 1 for a safety review and every 16 weeks for 48 weeks. The primary endpoint in the study is the time to either death,...
What is the current status of trial NCT00957242?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2009-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00957242?
The interventions under investigation include: placebo (DRUG), warfarin (DRUG).
Who is sponsoring clinical trial NCT00957242?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00957242's enrollment target sits among peer trials
145 1555th of 2000 higher than 442 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia